Association between serum uric acid levels and clinical outcomes of immunotherapy in advanced colorectal cancer patients.

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer, offering durable clinical benefits to a subset of patients. However, l…

Preview only. Read the full abstract at the source